Medtech IPOs have performed well in recent years, even outpacing other areas of the health industry, a top analyst said recently. The comments came as part of the MedTech Investing Conference in Minneapolis last week. Other industry executives at the conference also described a generally positive climate for medtech IPOs. In his presentation “Overview of […]
Your move, Ramius. The alternative investment firm and activist shareholder purchased a 12 percent stake in SurModics Inc. (NASDAQ:SRDX) because it saw a clear opportunity to boost the stock and turn a nice profit. In its quest to name three people to the SurModics board, Ramius said it did not want to break up the company or replace the board. That may no longer be the case.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
I guess SurModics Inc. (NASDAQ:SRDX) just responded. Just a day after the company based in Eden Prairie, Minnesota, said it would formally respond to Ramius LLC's efforts to name three people to its board of directors, SurModics announced late Tuesday it had named a new CEO and would explore a sale of its pharmaceuticals business.
Tornier Inc. is planning to test the choppy waters of Wall Street with an estimated $205 million initial public offering, according to documents filed with the Securities and Exchange Commission. The orthopedics firm in Edina, Minn., which specializes in devices to treat injuries to extremities and small bones, is the third local medical device company […]
St. Jude's purchase of Advanced Neuromodulation Systems In Texas has given the Minnesota medical device maker a much-needed boost in revenue at a time when global demand for mechanical heart devices starts to wane.
That bodes well for Minnesota's publicly traded medical device companies, including St. Jude Medical Inc., SurModics Inc. and Rochester Medical Corp., which were among the first to begin reporting fourth-quarter and yearly results last week.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.